D3 Bio (wuxi) Co., Ltd

This early-phase study is testing a new drug called D3L-001 in people with advanced solid tumors that have high levels of a protein called HER2. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 128 participants will recei…

This study tests a new oral drug called D3S-001, alone or with other cancer drugs, in people with advanced solid tumors that have a specific KRAS G12C mutation. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 442 participants will …

This early-phase trial tests an experimental drug called D3S-002, taken as a daily pill, in adults with advanced solid tumors that have MAPK pathway mutations. The study has two parts: first, finding a safe dose, and second, testing that dose alone or with another drug (D3S-001) …

This early-stage study tests a new drug, D3S-003, in people with advanced solid tumors that have a specific genetic change called KRAS p.G12D. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 42 participants whose cancer ha…